Home › FDA panel backs Novo Nordisk injection for obesity
 

Keywords :   


FDA panel backs Novo Nordisk injection for obesity

2014-09-12 00:55:12| Biotech - Topix.net

Federal health experts say Novo Nordisk's diabetes drug Victoza should be approved for a new use in treating obesity. The panel of Food and Drug Administration advisers voted 14-1 that the injectable drug's benefits outweigh its risks for patients who are obese or dangerously overweight.

Tags: panel novo injection backs

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05IMDA launches annual IMDA Awards Competition
20.05Registration opens for FTAs Fall Technical Conference 2024
20.05Voting begins for Colored By INX Can Design Contest
20.05New Study Highlights Biodegradability of Cotton and Cellulosic Microfibers
20.05New ACA-Published Industry Market Analysis for the Paint & Coatings Industry Now Available
20.05Ulta Beauty Launches Same-Day Delivery with DoorDash
20.05Nivea Crmes Limited-Edition Pride Tin Heralds New Initiative with PFLAG
20.05Sheboygan Paint Company Appoints New Technical Sales Representative
More »